American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 478-486 , March 2008

Incidence and Risk Factors for Diarrhea Following Kidney Transplantation and Association With Graft Loss and Mortality

  • Suphamai Bunnapradist, MD

      Affiliations

    • David Geffen School of Medicine, University of California, Los Angeles, CA
    • ,
  • Luca Neri, MD

      Affiliations

    • Department of Internal Medicine, Center for Outcomes Research, Saint Louis University School of Medicine, St Louis, MO
    • ,
  • Wendy Wong, MD

      Affiliations

    • Multiorgan Transplant Program, Cedars-Sinai Medical Center, Los Angeles, CA
    • ,
  • Krista L. Lentine, MD, MS

      Affiliations

    • Department of Internal Medicine, Center for Outcomes Research, Saint Louis University School of Medicine, St Louis, MO
    • Department of Internal Medicine, Division of Nephrology, Saint Louis University School of Medicine, St Louis, MO.
    • ,
  • Thomas E. Burroughs, PhD

      Affiliations

    • Department of Internal Medicine, Center for Outcomes Research, Saint Louis University School of Medicine, St Louis, MO
    • ,
  • Brett W. Pinsky, MPH

      Affiliations

    • Department of Internal Medicine, Center for Outcomes Research, Saint Louis University School of Medicine, St Louis, MO
    • ,
  • Steven K. Takemoto, PhD

      Affiliations

    • Department of Internal Medicine, Center for Outcomes Research, Saint Louis University School of Medicine, St Louis, MO
    • ,
  • Mark A. Schnitzler, PhD

      Affiliations

    • Department of Internal Medicine, Center for Outcomes Research, Saint Louis University School of Medicine, St Louis, MO
    • Corresponding Author InformationAddress correspondence to Mark A. Schnitzler, PhD, Associate Professor, Saint Louis University Center for Outcomes Research, 3545 Lafayette Ave, Salus Center, 2nd Floor, Rm 2825, St Louis, MO 63104.

Received 26 April 2007 ,Accepted 19 November 2007.

References 

  1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605–612
  2. Adams PL. Long-term patient survival: Strategies to improve overall health. Am J Kidney Dis. 2006;47(suppl 2):S65–S85
  3. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–185
  4. Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int. 2004;17:609–616
  5. Ponticelli C, Passerini P. Gastrointestinal complications in renal transplant recipients. Transpl Int. 2005;18:643–650
  6. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients (U.S. Renal Transplant Mycophenolate Mofetil Study Group). Transplantation. 1995;60:225–232
  7. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61:1029–1037
  8. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years (Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group). Transplantation. 1998;65:1450–1454
  9. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995;345:1321–1325
  10. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-Year results from the placebo-controlled trial. Transplantation. 1999;68:391–396
  11. Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients (FK506/MMF Dose-Ranging Kidney Transplant Study Group). Transplantation. 2000;69:875–880
  12. Squifflet JP, Backman L, Claesson K, et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation. 2001;72:63–69
  13. Chang HR, Lin CC, Lian JD. Early experience with enteric-coated mycophenolate sodium in de novo kidney transplant recipients. Transplant Proc. 2005;37:2066–2068
  14. Helderman JH, Goral S. Gastrointestinal complications of transplant immunosuppression. J Am Soc Nephrol. 2002;13:277–287
  15. Ducloux D, Ottignon Y, Semhoun-Ducloux S, et al. Mycophenolate mofetil-induced villous atrophy. Transplantation. 1998;66:1115–1116
  16. Maes B, Hadaya K, de Moor B, et al. Severe diarrhea in renal transplant patients: Results of the DIDACT Study. Am J Transplant. 2006;6:1466–1472
  17. Feldman M, Schiller LR. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann Intern Med. 1983;98:378–384
  18. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611–620
  19. Kambham N, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: A case-control study. Am J Surg Pathol. 2004;28:365–373
  20. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant. 2003;17:200–205
  21. Tierce JC, Porterfield-Baxa J, Petrilla AA, Kilburg A, Ferguson RM. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant. 2005;19:779–784
  22. Takemoto S, Pinsky B, Lentine K, Bunnapradist S, Burroughs T, Schnitzler M. Poor immunosuppression adherence: Associated factors and possible consequences. In: World Transplant Congress 2006 Poster Abstracts. Am J Transplant. 2006;6(Suppl 2):488
  23. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation. 2006;82:102–107
  24. Rubin RH. Gastrointestinal infectious disease complications following transplantation and their differentiation from immunosuppressant-induced gastrointestinal toxicities. Clin Transplant. 2001;15(suppl 4):S11–S22
  25. Ekberg H, Kyllonen L, Madsen S, Grave G, Solbu D, Holdaas H. Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipients. Transplantation. 2007;83:282–289
  26. Bolin P, Tanriover B, Lynn M, et al. Significant improvement of GI-symptoms burden in African-American transplant recipients after conversion to EC-MPS. Transplantation. 2006;82(suppl 2):S514–S515
  27. Chan L, Mulgaonkar S, Walker R, Arns W, Ambuhl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation. 2006;81:1290–1297

 Originally published online as doi:10.1053/j.ajkd.2007.11.013 on January 31, 2008.

PII: S0272-6386(07)01587-9

doi: 10.1053/j.ajkd.2007.11.013

American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 478-486 , March 2008

Article Tools